

**Ms. ANGELA WANGUI MAINA**

PID NO : H6151

Age : 23 Years Sex : Female

DOB: 22-Feb-2002



**Reference : DR. AISHA**

**Sample Collected At :**

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barsha South  
Third, Dubai

**VID : 5060110246**

Registered on :

30-Jun-2025 10:58 PM

Collected on :

30-Jun-2025 05:10 PM

Reported on :

30-Jun-2025 11:19 PM

| <u>Investigation</u>                              | <u>Observed Value</u> | <u>Flag</u> | <u>Unit</u>         | <u>Biological Reference Interval</u> | <u>Method</u>        |
|---------------------------------------------------|-----------------------|-------------|---------------------|--------------------------------------|----------------------|
| <b><u>COMPLETE BLOOD COUNT (CBC)</u></b>          |                       |             |                     |                                      |                      |
| HEMOGLOBIN                                        | 12.6                  |             | g/dL                | 12 - 15.5                            | Photometric          |
| RBC COUNT                                         | 4.3                   |             | 10 <sup>6</sup> /μL | 3.9 - 5                              | Electrical Impedance |
| HEMATOCRIT                                        | 38.0                  |             | %                   | 35 - 45                              | Calculation          |
| MCV                                               | 87.8                  |             | fL                  | 82 - 98                              | Calculation          |
| MCH                                               | 29.2                  |             | pg                  | 27 - 32                              | Calculation          |
| MCHC                                              | 33.3                  |             | g/dL                | 32 - 37                              | Calculation          |
| * RDW                                             | 13.1                  |             | %                   | 11.9 - 15.5                          | Calculation          |
| * RDW-SD                                          | 39.80                 |             | fL                  |                                      | Calculation          |
| MPV                                               | 8.4                   |             | fL                  | 7.6 - 10.8                           | Calculation          |
| PLATELET COUNT                                    | 341                   |             | 10 <sup>3</sup> /uL | 150 - 450                            | Electrical Impedance |
| * NUCLEATED RBC (NRBC)                            | 0.0                   |             | /100 WBC            |                                      | VCS 360 Technology   |
| * ABSOLUTE NRBC COUNT                             | 0.0                   |             | 10 <sup>3</sup> /uL |                                      | Calculation          |
| <b><u>TOTAL &amp; DIFFERENTIAL COUNT (DC)</u></b> |                       |             |                     |                                      |                      |
| WBC COUNT                                         | 8.2                   |             | 10 <sup>3</sup> /μL | 4 - 11                               | Electrical Impedance |
| NEUTROPHILS                                       | 65                    |             | %                   | 40 - 75                              | VCS 360 Technology   |
| LYMPHOCYTES                                       | 29                    | L           | %                   | 30 - 60                              | VCS 360 Technology   |
| EOSINOPHILS                                       | 3                     |             | %                   | 0 - 6                                | VCS 360 Technology   |
| MONOCYTES                                         | 3                     |             | %                   | 1 - 6                                | VCS 360 Technology   |
| BASOPHILS                                         | 0                     |             | %                   | 0 - 1                                | VCS 360 Technology   |
| <b><u>ABSOLUTE COUNT</u></b>                      |                       |             |                     |                                      |                      |
| ABSOLUTE NEUTROPHIL COUNT                         | 5.3                   |             | 10 <sup>3</sup> /uL | 1.6 - 8.25                           | Calculation          |
| ABSOLUTE LYMPHOCYTE COUNT                         | 2.4                   |             | 10 <sup>3</sup> /uL | 1.2 - 6.6                            | Calculation          |
| ABSOLUTE MONOCYTE COUNT                           | 0.2                   |             | 10 <sup>3</sup> /uL | 0.04 - 0.66                          | Calculation          |
| ABSOLUTE EOSINOPHIL COUNT                         | 0.2                   |             | 10 <sup>3</sup> /uL | 0 - 0.66                             | Calculation          |
| ABSOLUTE BASOPHIL COUNT                           | 0                     |             | 10 <sup>3</sup> /uL | 0 - 0.11                             | Calculation          |

**Sample Type:** EDTA Whole Blood

**DR. ADLEY MARK FERNANDES**  
M.D (Pathology)  
Pathologist

*Vyoma V. Shah*

**DR. VYOMA SHAH**  
M.D (Pathology)  
Clinical Pathologist

*Jaladini Dulanka*


**JALADINI DULANKA**  
Laboratory Technologist

This is an Electronically Authenticated Report.

Printed on: 01-Jul-2025 12:04 AM

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (\*).  
Test marked with # is performed in an accredited referral laboratory.





**Ms. ANGELA WANGUI MAINA**

PID NO : H6151

Age : 23 Years Sex : Female

DOB: 22-Feb-2002



**Reference : DR. AISHA**

**Sample Collected At :**

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barsha South  
Third, Dubai

**VID : 5060110246**

Registered on :

30-Jun-2025 10:58 PM

Collected on :

30-Jun-2025 05:10 PM

Reported on :

01-Jul-2025 12:03 AM

| Investigation                                                                             | Observed Value | Flag | Unit | Biological Reference Interval                      |
|-------------------------------------------------------------------------------------------|----------------|------|------|----------------------------------------------------|
| <b>* C-REACTIVE PROTEIN (CRP)</b><br>(Serum, Particle-enhanced immunoturbidimetric assay) | <b>29</b>      | H    | mg/L | < 5.0<br>Please note change.<br>Source: Roche IFU. |

Note: Please correlate clinically.

**INTERPRETATION :**

- CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
- CRP response may be less pronounced in patients suffering from liver disease.
- CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection."

----- End Of Report -----

**DR. ADLEY MARK FERNANDES**  
M.D (Pathology)  
Pathologist

*Dr. Vyoma Shah*

**DR. VYOMA SHAH**  
M.D (Pathology)  
Clinical Pathologist



**M RASHID CHENANGADATH**  
Laboratory Technologist

This is an Electronically Authenticated Report.

Printed on: 01-Jul-2025 12:04 AM

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (\*).  
Test marked with # is performed in an accredited referral laboratory.



**CAP**  
ACCREDITED  
COLLEGE of AMERICAN PATHOLOGISTS

**elaci**  
Emirates International Accreditation Centre  
192 - LB - MED